GlassScriptPhysician profile
Matthew Keathley
NPI 1396581526
$1,834.33
in general payments reported to CMS, 2019-2025
17 companies · $1,125 in 2025
The $1,125 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $709 · 2025: $1,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,834.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $349.83 | 2024-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $344.86 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $281.11 | 2024-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.01 | 2024-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $119.14 | 2024-2025 | Eliquis |
| Philips North America LLC | $94.13 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Novo Nordisk INC | $90.50 | 2024-2025 | Wegovy, Ozempic |
| Actelion Pharmaceuticals US, INC. | $83.83 | 2025 | Opsumit, Uptravi, Opsynvi |
| Pfizer INC. | $81.76 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $35.25 | 2024 | |
| Merck Sharp & Dohme LLC | $28.01 | 2024 | Winrevair |
| Daiichi Sankyo INC. | $27.06 | 2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $25.16 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $19.52 | 2024 | Evkeeza |
| Cvrx, INC. | $16.57 | 2025 | Barostim Neo System |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $15.48 | 2024 | Farxiga |
| Olympus America INC. | $14.11 | 2025 | Itind System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Keathley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.